BioSpace News Archive

2seventy bio, Inc., a leading immuno-oncology cell therapy company, will present preclinical data on bbT369, an investigational novel CD79a/CD20 dual-targeting CBLB gene edited CAR T cell therapy at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.

Avivagen Inc. announced the results of its annual general meeting of shareholders and highlighted the significant progress made in the Corporation’s efforts to drive further adoption of OxC-betaTM worldwide.

PTC Therapeutics, Inc. announced that on April 8, 2022, the company approved non-statutory stock options to purchase an aggregate of 86,130 shares of its common stock and 33,125 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 96 new employees.

Kiromic BioPharma, Inc., a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, announces financial results for the fourth quarter and fiscal year ended December 31, 2021.

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, released preclinical data on its product candidate UCART20x22 at the American Association for Cancer Research Annual Meeting.

Ligand Pharmaceuticals Incorporated announced that on April 8, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock to Kurt Gustafson, who joined OmniAb, Inc., Ligand’s antibody discovery business, as its CFO, in connection with his commencement of employment.

NANOBIOTIX announced the filing of its universal registration document for the financial year ended December 31, 2021 with the French financial market authority, as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2021 with the U.S. Securities and Exchange Commission.

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), today announced new nonclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) STRO-002, in an e-poster session, at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.

Cardiff Oncology, Inc. (Nasdaq: CRDF), today announced the results of preclinical studies evaluating the anti-cancer activity of onvansertib in combination with the PARP inhibitor (PARPi) olaparib in PARPi-resistant patient-derived xenograft (PDX) ovarian cancer models.